Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Modern Molecular Taxonomy01:29

Modern Molecular Taxonomy

836
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...
836

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.

Experimental hematology·2026
Same author

Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.

Blood advances·2026
Same author

Evaluation of Long-Read Genome Sequencing for Genomic Profiling of Myeloid Cancers.

The Journal of molecular diagnostics : JMD·2025
Same author

A clinical guide to TP53 mutations in myeloid neoplasms.

Blood·2025
Same author

Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy.

Nature genetics·2025
Same author

How chemotherapy shapes hematopoietic stem cells.

Nature genetics·2025

Related Experiment Video

Updated: May 1, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K

Molecular genetics of AML.

Daniel C Link1

  • 1Division of Oncology, Department of Medicine, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8007, Saint Louis, MO 63110, USA. dlink@dom.wustl.edu

Best Practice & Research. Clinical Haematology
|December 4, 2012
PubMed
Summary

Whole-genome sequencing reveals numerous mutations in acute myeloid leukemia (AML) genomes, including novel driver mutations. Understanding cancer genome heterogeneity is crucial for optimizing AML treatment strategies.

Area of Science:

  • Genomics
  • Oncology
  • Molecular Biology

Background:

  • Technological advances enable whole-genome sequencing (WGS) for cancer genome interrogation.
  • Nearly 40 acute myeloid leukemia (AML) tumor genomes have been sequenced.
  • AML genomes exhibit significant mutational burden and complexity.

Purpose of the Study:

  • To analyze the mutational landscape of acute myeloid leukemia (AML) using whole-genome sequencing.
  • To identify novel driver mutations in AML.
  • To investigate clonal heterogeneity in AML and its implications for therapy.

Main Methods:

  • Whole-genome sequencing (WGS) of nearly 40 acute myeloid leukemia (AML) cases.
  • Analysis of mutation profiles, including coding and non-coding mutations.

More Related Videos

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

8.2K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951

Related Experiment Videos

Last Updated: May 1, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K
Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

8.2K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951
  • Assessment of clonal heterogeneity using digital sequencing data.

    • Main Results:

    • Each AML genome averages approximately 400 mutations, with 6-26 coding mutations.
    • The majority of mutations are background mutations from hematopoietic stem cell aging.
    • Novel driver mutations in AML have been identified through WGS.
    • Clonal heterogeneity is prevalent at AML diagnosis, with subclones potentially driving relapse.

    Conclusions:

    • Whole-genome sequencing provides unprecedented resolution for cancer genome analysis.
    • Identifying driver mutations and understanding clonal heterogeneity are key challenges in AML.
    • Assessing clonal heterogeneity is essential for optimizing AML therapy.
    • WGS is expected to become a routine diagnostic tool for AML and other cancers.